SCHEMBL3014785

SCHEMBL3014785

CCOc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(C(F)(F)F)c4)CC3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
HTT P42858 1/20 0.47
KDM4E B2RXH2 2/20 0.47
HSD11B1 P28845 1/20 0.47
GBA1 P04062 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PKM P14618 1/20 0.41
PKLR P30613 1/20 0.41
KDM2B Q8NHM5 1/20 0.41
TSHR P16473 1/20 0.41
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653091 0.96 POLB (0.46) POLBHTTKDM4EHSD11B1GBA1
SCHEMBL3002340 0.92 L3MBTL1 (0.50) POLBHTTKDM4EHSD11B1GBA1
SCHEMBL3016124 0.91 HTT (0.51) POLBHTTKDM4EHSD11B1GBA1
SCHEMBL3007892 0.89 MAPT (0.47) POLBKDM4EGBA1SMN1; SMN2L3MBTL1
SCHEMBL3019668 0.89 HTT (0.49) POLBHTTKDM4EHSD11B1GBA1
SCHEMBL3009537 0.89 POLB (0.52) POLBHTTKDM4EHSD11B1GBA1
SCHEMBL3653259 0.88 L3MBTL1 (0.47) POLBHTTKDM4EHSD11B1GBA1
SCHEMBL3012643 0.88 HTT (0.59) POLBHTTKDM4EHSD11B1GBA1
SCHEMBL3001708 0.87 TDP1 (0.47) POLBKDM4EHSD11B1GBA1SMN1; SMN2
SCHEMBL3015994 0.87 MEN1 (0.44) POLBKDM4EGBA1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885HTT 2/4885KDM4E 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.